| Name | Title | Contact Details |
|---|
LifeScan is a global leader in blood glucose monitoring innovation and digital health technology and has a vision to create a world without limits for people with diabetes and related conditions. More than 20 million people and their caregivers around the world count on LifeScan’s OneTouch brand products to manage their diabetes. Together, LifeScan and OneTouch improve the quality of life for people with diabetes with products and digital platforms defined by simplicity, accuracy, and trust.
Kinex Medical Company is a Waukesha, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
InCube Ventures is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
LuxCath is the leader in using fluorescence and optics to directly view lesions during cardiac ablation procedures. The company`s breakthrough technology offers the potential for dramatic evolution in the way ablation procedures are performed by assessing tissue contact and enabling direct lesion progression monitoring. LuxCath`s patented solution aims to ensure the quality of catheter lesions at the moment they are made. LuxCath enables constant optical tissue contact assessment and provides valuable lesion formation and progression information during each ablation.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy. Â